Sto Nanomedical seeks delisting from Nasdaq First North for financing
What happened
Sto Nanomedical AB resolved to apply for delisting from the Nasdaq First North Growth Market. The company stated the move is intended to create better conditions for financing the next phase of Tumorad development with specialist investors. The extraordinary general meeting is planned for November 19, 2026, and the application for delisting is expected to be submitted no earlier than January 25, 2027.
From pr-inside.com
Why it matters
The delisting is a strategic move by Sto Nanomedical to secure capital for the continued advancement of Tumorad, a cancer treatment. Tumorad-01 has already shown positive results, establishing the maximum tolerated dose and observing clear tumor uptake in patients with head and neck cancer.
From pr-inside.com
Who's involved
- StoCompany seeking delisting to finance Tumorad development
- Jonathan MorrisChairman of the Board for Sto Nanomedical
- FDAFormally regulates Sto Nanomedical's pharmaceutical products
- Carola LemneChairperson within Sto Nanomedical
- Fahad KhanBoard member of the Hilbert Group, which governs Sto Nanomedical
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- StoSpeculative
Sto Nanomedical could secure funding through the delisting process to increase investment in the next phase of Tumorad's clinical trials.